Duchenne Group's Presentation Is Milestone For Patient Involvement
Executive Summary
Advocacy group gets portion of Sarepta's formal presentation period to present eteplirsen patient experience data, believed to be a first for an advisory committee meeting. Will it become commonplace?
You may also be interested in...
Sarepta Tells Patients To Stand Down, Golodirsen Future 'Our Responsibility'
Patient advocates asked what they could do after US FDA’s complete response letter for the proposed Duchenne drug, but Sarepta's CEO said the company would get the product back on track to approval itself, a marked contrast to engaged role the community played the last time the firm ran into a roadblock at the agency.
US FDA Mulling Core Criteria For Patient-Reported Outcomes
Agency wants public comment on creating clinical outcome assessments that could be adaptable to multiple trials.
US FDA Planning Another Patient Group To Boost Involvement
Patient Engagement Collaborative expected to invite stakeholders to discuss how patient interaction with FDA can improve.